Expert panel of 6 key opinion leaders in dermatology consensus panel unanimously approved eleven usage guidelines and consensus supporting statements for the appropriate use of GEP testing

Comparison of the i31-GEP for SLNB to the MIA nomogram in patients with T1-T2 tumors with complete data (n=582). The precision of each tool to identify patients with <5% SLN positivity risk was analyzed using 95% confidence intervals.

Study compared the i31-GEP for SLNB with the CP-GEP to identify patients who can safely forego SLNB.

Utilizing patient data provided through collaboration with the NCI SEER program (diagnosis 2016-2018) the 31-GEP class results was a statistically significant independent predictor of MSS and can help identiy patients with low risk of death who may potentially forego unnecessary procedures

TissueCypher may be a practical and effective solution to the lack of standardization of expert pathology review of LGD as advocated by all guidelines.

Patient Survery performed in conjunction with Melanoma Research Foundation on patient attitudes towards prognostic testing

Treatment decisions for patients with cutaneous squamous cell carcinoma (cSCC) are traditionally based upon clinicopathologic risk factors and staging systems. Due to the accuracy limitations of these resources in predicting poor outcomes, there is a clinically significant need for more accurate methods of risk assessment. T

Validation of the integration the 31-GEP testing with clinpath features for invidialized risk assessment of MSS, DMFS, and RFS

Histological review of community-based LGD showed a high inter-observer variability with a signification number of cases classified as non-informative.

Utilizing patient data provided through collaboration with the NCI SEER program in patients with Stage I-III CM, 31-GEP class result was a significant independent predistor of both MSS and OS. Patients with 31-GEP results in addition to clinicopathologic factors had improved survival.

Prospective multicenter study showed that integration of 31-GEP and T stage can gain clinically useful prognostic information from data obtained noninvasively.

DecisionDx-Melanoma data significantly stratified MSS in stage I, II, and III patients. This test has also demonstrated high specificity and NPV for melanoma-specific mortality (MSM)